Immunoprofile of Ovarian Tumors With Putative Transitional Cell (Urothelial) Differentiation Using Novel Urothelial Markers: Histogenetic and Diagnostic Implications

American Journal of Surgical Pathology

Volumn 27, Issue 11, 2003, Pages 1434-1441

  Logani, Sanjay ^a,c   Oliva, Esther ^b   Amin, Mahul B ^a   Folpe, Andrew L ^a   Cohen, Cynthia ^a   Young, Robert H ^b  

^a University School of Medicine   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Brenner tumor; Immunohistochemistry; Thrombomodulin; Transitional cell carcinoma of ovary; Uroplakin III

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7; THROMBOMODULIN; TUMOR PROTEIN; UROPLAKIN; WT1 PROTEIN;

ARTICLE; BLADDER CARCINOMA; BRENNER TUMOR; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; OVARY TUMOR; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

BRENNER TUMOR; CARCINOMA, TRANSITIONAL CELL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; OVARIAN NEOPLASMS; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 0142232026     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200311000-00005     Document Type: Article

References (39)

1. Appleton MA, Attanoos RL, Jasani B. Thrombomodulin as a marker of vascular and lymphatic rumours. Histopathology. 1996;29:153-157.
2. Arey LB. The origin and form of Brenner rumor. Am J Obstet Gynecol. 1961;81:743-751.
3. Attanoos RL, Goddard H, Gibbs AR. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma. Histopathology, 1996;29:209-215.
4. Berezowski K, Stastny JF, Komstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426-429.
5. Bransilver B, Ferenczy A, Richart RM. Brenner tumors and Walthard cell nests. Arch Pathol. 1974;98:76-86.
6. Brenner F. Das Oophoroma Folliculare. Frankfurt Z Pathol. 1907;1:150-171.
7. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
8. Chu PG, Weiss LM. Keratin expressions in human tissues and neoplasms. Histopathology. 2002;40:403-439.
9. Groutz A, Gillon G, Shimonov M, et al. Late, isolated, secondary ovarian transitional cell carcinoma: an unusual course of bladder malignancy. Br J Urol. 1996;78:795-796.
10. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981:29:577-580.
11. Kardar AH, Lindstedt EM, Tulbah AM, et al. Metastatic transitional cell carcinoma of the ovary from superficial bladder tumour. Scand J Urol Nephrol 1998;32:73-76.
12. Kaufmann O, Volmerig J, Dietel M. Uroplakin II1 is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683-687.
13. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25:1074-1078.
14. Merkow LP, Salazar H, Pardo M. Human ovarian neoplasms: light and electron microscopic correlation: I. Brenner tumours. Obstet Gynecol. 1972;40:667-680.
15. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002;33:1136-1140.
16. Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol. 1995;8:384-388.
17. Moll R, Wu XR, Lin JH, et al. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147:1383-1397.
18. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
19. Moll R, Achtstatter T, Becht E, et al. Cytokeratins in normal and malignant transitional epithelium: maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines. Am J Pathol. 1988;132:123-144.
20. Moll R, Lowe A, Laufer J, et al. Cytokeratin 20 in human carcinomas: a new histogenetic marker detected by monoclonal antibodies. Am J Pathol. 1992;140:427-447.
21. Ogawa K, Johansson SL, Cohen SM. Immunohistochemical analysis of uroplakins, urothelial specific proteins in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. Am J Pathol. 1999;155:1047-1050.
22. Oliva E, Musulen E, Part J, Young RH. Transitional cell carcinoma of the renal pelvis with symptomatic ovarian metastases. Int J Surg Pathol. 1995;2:231-236.
23. Ordóñez NG. Thrombomodulin expression in transitional cell carcinoma. Am J Clin Pathol. 1998;110:385-390.
24. Ordóñez NG. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different. Histopathology. 2000;36:433-438.
25. Ordóñez NG, Mackay B. Brenner rumor of the ovary: a comparative immunohistochemical and ultrastructural study with transitional cell carcinoma of the bladder. Ultrastructural Pathol. 2000;24:157-167.
26. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin and cytokeratin 20 in noninvasive, invasive and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
27. Riedel I, Czernobilsky B, Lifschitz-Mercer B, et al. Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch. 2001;438:181-191.
28. Scully RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube and Broad Ligament. Washington, DC: Armed Forces Institute of Pathology, 1998:153-163.
29. Scully RE. Recent progress in ovarian cancer. Hum Pathol. 1970;1:73-98.
30. Scully RE. Histological Typing of Ovarian Tumours: World Health Organization International Histological Classification of Tumours. Berlin: Springer-Verlag, 1999.
31. Shevchuk MM, Fenoglio CM, Richart RM. Histogenesis of Brenner tumors: I. Histology and ultrastrucrure. Cancer. 1980;46:2607-2616.
32. Shevchuk MM, Fenoglio CM, Richart RM. Histogenesis of Brenner tumors: II. Histochemistry and CEA. Cancer. 1980;46:2617-2622.
33. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163.
34. Silverberg SG. Brenner tumors of the ovary. Cancer. 1971;28:588-596.
35. Soslow RA, Rouse RV, Hendrickson MR, et al. Transitional cell neoplasms of the ovary and urinary bladder: a comparative immunohistochemical analysis. Int J Gynecol Pathol. 1996;15:257-265.
36. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
37. Wu XR, Sun TT. Molecular cloning of a 47 kDa tissue-specific and differentiation-dependent urothelial cell surface glycoprotein. J Cell Sci. 1993;106:31-43.
38. Wu XR, Lin JH, Walz T, et al. Mammalian uroplakins: a group of highly conserved urothelial differentiation-related membrane proteins. J Biol Chem. 1994;269:13716-13724.
39. Young RH, Scully RE. Urothelial and ovarian carcinomas of identical cell types: problems in interpretation. A report of three cases and review of the literature. Int J Gynecol Pathol. 1988;7:197-211.